Market Trends of Chronic Lower Back Pain (CLBP) Industry
The Chronic back pain Segment is Expected to Hold a Major Share in Pain Type of the Chronic Lower Back Pain (CLBP) Market.
The chronic back pain segment is expected to increase significantly during the forecast period due to the rising prevalence of chronic back pain cases and the overall diagnostic adoption rate. For instance, in an article published by StatPearls in February 2023, back discomfort is joint in adults, and 23% of adults suffer from chronic low back discomfort. This recurrence rate was 24% to 80% in their lifetime. Thus, the high recurrence rate of lower back pain is expected to drive segmental growth.
Similarly, an article published by the Lancet Rheumatology in June 2023 stated that 619 million people worldwide suffered from low back pain in 2020, and by 2050, that number is expected to reach 843 million. Thus, the global low back pain epidemic is escalating and expected to drive the market segment.
Moreover, an article published by PubMed in October 2022 stated that most chronic low back pain was 4.2% in people aged 24 to 39 and 19.6% in people aged 20 to 59. Six studies with people aged 18 and up indicated chronic low back pain prevalence ranging from 3.9% to 10.2%, while three reported prevalence ranging from 13.1% to 20.3%.
As per the same source, the majority of chronic low back pain in the Brazilian elderly population was 25.4%. Lower back discomfort is anticipated to rise in future years, boosting the segmental market growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do the Same in the Forecast Period
North America has an increasing number of chronic back pain is expected to drive the market. For instance, according to the Center on an Aging Society (CAS) article published in October 2022, approximately 16 million adults that are 8% of all individuals, suffered from persistent chronic back pain, limiting their ability to do daily tasks, making that sixth most expensive medical problem in the United States.
Similarly, an article published by Red Cross Therapy (RCT) in December 2022 stated that approximately 80% of Americans experience back pain at least once a year around 8% of people aged 18 and up suffer from chronic back pain to the point where their activities are severely limited. This is expected to increase various treatment adoption in the region and expected to boost the growth in the market.
Product approvals are expected to boost the market growth in the region. For instance, in October 2022, Nevro Corp. had received approval from the United States Food and Drug Administration (FDA) for the Senza HFX iQ spinal cord stimulation (SCS) system. Therefore, such approvals of various regional products are expected to drive the market.
